 In this dynamic era for the life sciences industries, science is not the only element that is rapidly changing. Historically, revenue and margin growth have been driven by product, portfolio and value chain growth. Today, new products and geographic market growth are playing an increasingly prominent role in the bottom line. What is driving this change? Increased regulatory scrutiny, patent expirations, generic substitutions, depleted pipelines, price pressures and controls, and the emerging global market are forcing life sciences companies to focus on enterprisewide growth, rather than traditional growth areas. Glenn Snyder, principal, Dennis Hubbard, senior manager, and Chris Geissler, manager, all from Deloitte Consulting LLP, outline the challenges and provide a framework of six emerging strategic decision and operational areas to boost revenue growth and margins in the March 2007 issue of Future Pharmaceuticals. These strategic decision and operational areas include:
Pricing and reimbursement strategy Distribution strategy Contract strategy Customer support Order management Contract administration
Learn how to best leverage activity in the above areas to maximize revenue growth in the attached article. Posted with permission from the publisher. Related Content:
Report: Smoother Sailing in the Distribution Channel |
